Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BiPar Sciences has announced encouraging preclinical data demonstrating the activity of its lead poly ADP-ribose polymerase inhibitor, BSI-201, in ovarian cancer models. The results highlight the anti-tumor activity of BSI-201 through PARP activity inhibition, tumor growth suppression, and extended survival in multi-drug resistant xenograft models of ovarian cancer.
Subscribe to our email newsletter
The data evaluated BSI-201 as both a single agent and in combination with topotecan in human OVCAR-3 xenografts resistant to adriamycin, melphalan and cisplatin. Administered as monotherapy, BSI-201 demonstrated significant tumor growth delay and improved survival. In combination with topotecan, BSI-201 significantly inhibited tumor growth and increased the percentage of complete tumor regressions, compared with topotecan alone.
Based on the preclinical findings and positive Phase I results, BiPar is currently enrolling in a clinical trial of BSI-201 in combination with topotecan in advanced ovarian cancer and will soon launch a Phase II monotherapy trial in BRCA-negative ovarian cancer patients. These ovarian cancer trials are said to represent an important expansion of BiPar’s on-going Phase II programs in breast and brain cancer patients.
Hoyoung Huh, president and CEO of BiPar, said: “BSI-201 represents an innovative therapeutic candidate which is well positioned as both monotherapy and combination treatment in multiple solid tumor settings including ovarian cancer.”